HepatologyNews.net

Hepatology Xagena

Although direct-acting antiviral ( DAA ) therapies for chronic hepatitis C virus ( HCV ) infection have demonstrated high rates of sustained virologic response, virologic failure may still occur, pote ...


Detailed results from an open-label phase 2 trial evaluating the investigational apoptosis signal-regulating kinase 1 ( ASK1 ) inhibitor Selonsertib ( formerly GS-4997 ) alone or in combination with t ...


Real-world effectiveness data are needed to inform hepatitis C virus ( HCV ) treatment decisions. The uptake of Ledipasvir and Sofosbuvir ( LDV/SOF; Harvoni ) regimens across health care settings has ...


Detailed 48-week results from two large phase 3 clinical trials ( Studies 108 and 110 ) evaluating once-daily Tenofovir alafenamide ( TAF ) 25 mg in treatment-naïve and treatment-experienced adults wi ...


Data has demonstrated that choosing a different combination of direct-acting antiviral ( DAA ) treatment for hepatitis C can eradicate the virus at four weeks in patients who had already failed on pre ...


A pilot study found that all patients with acute HCV who were treated with a direct-acting antiviral treatment over a short-duration of six weeks had undetectable HCV after a 12 week follow-up. The ...


New data has confirmed that a novel first-in-class treatment for hepatitis B, called NVR 3-778, is well-tolerated and can reduce levels of the virus’ genetic material in the body when combined with Pe ...


A hepatitis C ( HCV ) drug currently under investigation, ABT-493 and ABT-530, which is an all-oral once-daily antiviral treatment, helped HCV genotype 3 patients with heavily scarred livers and no pr ...


Interim results from one of the ongoing phase II studies of RG-101 for the treatment of hepatitis C virus infection ( HCV ) were announced. The study was designed to evaluate a shortened, 4-week tr ...


A study has evaluated the clinical outcomes of Telaprevir- or Simeprevir-based triple therapy for recurrent hepatitis C after living donor liver transplantation. Twenty-six patients received antiv ...


Six treatment options are available in 2015 for patients infected with HCV genotype 1, including two IFN-containing regimens and four IFN-free regimens. The combination of Sofosbuvir and Ribavirin s ...


All treatment-naïve and –experienced patients with compensated or decompensated chronic liver disease related to ( hepatitis C virus ) HCV, who are willing to be treated and who have no contra-indicat ...


Significant clinical variations exist among patients with hepatocellular carcinoma ( HCC ), the most common type of liver cancer, depending on the viral cause of the disease, hepatitis B virus ( HBV ) ...


Vitamin D receptors ( VDR ) bind calcitriol and modulate several physiological systems through genomic and nongenomic pathways. Calcitriol stimulates store-operated channels Ca influx by translocation ...


Interferon-based treatment is not suitable for many patients with hepatitis C virus ( HCV ) infection because of contraindications such as psychiatric illness, and a high burden of adverse events. L ...